Please wait a minute...
浙江大学学报（医学版）
浙江大学学报（医学版）  2019, Vol. 48 Issue (2): 142-147    DOI: 10.3785/j.issn.1008-9292.2019.04.04
子宫腺肌病非手术治疗     
子宫腺肌病患者药物治疗进展
BabooKalianee Devi(),陈正云,张信美*()
浙江大学医学院附属妇产科医院妇二科, 浙江 杭州 310006
Progress on medical treatment in the management of adenomyosis
Baboo Kalianee Devi(),CHEN Zhengyun,ZHANG Xinmei*()
Department of Gynecology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China
 全文: PDF(908 KB)   HTML( 12 )
摘要：

药物治疗在缓解子宫腺肌病患者相关症状、提高手术疗效、延缓疾病进展和促进辅助生育方面具有重要的作用。非甾体抗炎药是控制子宫腺肌病相关疼痛的首选药物，是近期有生育要求患者的唯一选择；甾体激素、促性腺激素释放激素激动剂和米非司酮等药物可有效减轻疼痛和控制子宫出血，其中以口服避孕药、左炔诺孕酮宫内节育系统（曼月乐）和地诺孕素等甾体激素的疗效更确切。目前尚无用于子宫腺肌病的特效药物，应根据患者的年龄、症状、子宫大小、生育要求和经济条件等情况选择性应用，但停药后症状易复发。因此，子宫腺肌病患者药物长期应用有待进一步研究。
关键词： 子宫腺肌病;  药物疗法;  综述    
Abstract:

Drug therapy plays an important role in alleviating the symptoms related to adenomyosis, improving the curative effect of surgery, delaying the progress of disease and promoting assisted reproduction. Non-steroidal anti-inflammatory drugs (NSAIDs) are the first choice to control pain associated with adenomyosis, and are the only choice for patients with recent fertility requirements; steroid hormones, gonadotropin releasing hormone agonists and mifepristone can effectively relieve pain and control uterine bleeding, among which oral contraceptives, levonorgestrel-releasing intranterine system (Mirena) and dienogest are more effective and commonly used in clinic. Drug selection should be based on patient's age, symptoms, uterine size, fertility requirements and economical conditions. At present, there is no specific drug for adenomyosis, and symptoms are easy to recur after drug withdrawal, so the long-term drug use needs further study.
Key words: Adenomyosis    Drug therapy    Review
收稿日期: 2019-01-26 出版日期: 2019-07-24
CLC:  R711.74  
基金资助: 国家重点研发计划(2017YFC1001200)
通讯作者: 张信美     E-mail: 21618649@zju.edu.cn;zhangxinm@zju.edu.cn
作者简介: Baboo Kalianee Devi(1991-), 女, 硕士研究生, 主要从事子宫内膜异位症研究; E-mail:21618649@zju.edu.cn; https://orcid.org/0000-0002-6364-2647
服务　　
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章　　
BabooKalianee Devi
陈正云
张信美

引用本文:

BabooKalianee Devi,陈正云,张信美. 子宫腺肌病患者药物治疗进展[J]. 浙江大学学报（医学版）, 2019, 48(2): 142-147.

Baboo Kalianee Devi,CHEN Zhengyun,ZHANG Xinmei. Progress on medical treatment in the management of adenomyosis. J Zhejiang Univ (Med Sci), 2019, 48(2): 142-147.

链接本文:

http://www.zjujournals.com/med/CN/10.3785/j.issn.1008-9292.2019.04.04    或    http://www.zjujournals.com/med/CN/Y2019/V48/I2/142

1 MARJORIBANKS J , AYELEKE R O , FARQUHAR C et al. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea[J]. Cochrane Database Syst Rev, 2015, (7): CD001751
2 LETHABY A , AUGOOD C , DUCKITT K et al. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding[J]. Cochrane Database Syst Rev, 2007, (4): CD000400
3 ITAM S P, AYENSU-COKER L, SANCHEZ J, et al. Adenomyosis in the adolescent population: a case report and review of the literature[J/OL]. J Pediatr Adolesc Gynecol, 2009, 22(5): e146-e147.
4 SCHAFER A I . Effects of nonsteroidal anti-inflammatory therapy on platelets[J]. Am J Med, 1999, 106 (5B): 25S- 36S
5 HAWKEY C J . COX-2 inhibitors[J]. Lancet, 1999, 353 (9149): 307- 314
doi: 10.1016/S0140-6736(98)12154-2
6 VERCELLINI P , VIGANò P , SOMIGLIANA E et al. Endometriosis:pathogenesis and treatment[J]. Nat Rev Endocrinol, 2014, 10 (5): 261- 275
doi: 10.1038/nrendo.2013.255
7 TSUI K H , LEE W L , CHEN C Y et al. Medical treatment for adenomyosis and/or adenomyoma[J]. Taiwan J Obstet Gynecol, 2014, 53 (4): 459- 465
doi: 10.1016/j.tjog.2014.04.024
8 SHAABAN O M , ALI M K , SABRA A M et al. Levonorgestrel-releasing intrauterine system versus a low-dose combined oral contraceptive for treatment of adenomyotic uteri:a randomized clinical trial[J]. Contraception, 2015, 92 (4): 301- 307
doi: 10.1016/j.contraception.2015.05.015
9 FERRERO S , REMORGIDA V , VENTURINI P L . Endometriosis[J]. BMJ Clin Evid, 2010, 2010 pii:0802
10 STEGEMAN B H , DE BASTOS M , ROSENDAAL F R et al. Different combined oral contraceptives and the risk of venous thrombosis:systematic review and network meta-analysis[J]. BMJ, 2013, 347 f5298
doi: 10.1136/bmj.f5298
11 RADZINSKY V E , KHAMOSHINA M B , NOSENKO E N et al. Treatment strategies for pelvic pain associated with adenomyosis[J]. Gynecol Endocrinol, 2016, 32 (sup2): 19- 22
doi: 10.1080/09513590.2016.1232673
12 SHENG J , ZHANG W Y , ZHANG J P et al. The LNG-IUS study on adenomyosis:a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis[J]. Contraception, 2009, 79 (3): 189- 193
doi: 10.1016/j.contraception.2008.11.004
13 李雷, 冷金花, 史精华 et al. LNG-IUS治疗子宫腺肌病相关经量过多的前瞻性研究[J]. 中华妇产科杂志, 2016, 51 (6): 424- 430
LI Lei , LENG Jinhua , SHI Jinhua et al. A prospective study on the effects of levonorgestrel-releasing intrauterine system for adenomyosis with menorrhagia[J]. Chinese Journal of Obstetrics and Gynecology, 2016, 51 (6): 424- 430
doi: 10.3760/cma.j.issn.0529-567x.2016.06.005
14 PETTA C A , FERRIANI R A , ABRAO M S et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis[J]. Hum Reprod, 2005, 20 (7): 1993- 1998
doi: 10.1093/humrep/deh869
15 KRIPLANI A , SINGH B M , LAL S et al. Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagia[J]. Int J Gynaecol Obstet, 2007, 97 (3): 190- 194
doi: 10.1016/j.ijgo.2007.01.009
16 LEE K H , KIM J K , LEE M A et al. Relationship between uterine volume and discontinuation of treatment with levonorgestrel-releasing intrauterine devices in patients with adenomyosis[J]. Arch Gynecol Obstet, 2016, 294 (3): 561- 566
doi: 10.1007/s00404-016-4105-y
17 ZHANG P , SONG K , LI L et al. Efficacy of combined levonorgestrel-releasing intrauterine system with gonadotropin-releasing hormone analog for the treatment of adenomyosis[J]. Med Princ Pract, 2013, 22 (5): 480- 483
doi: 10.1159/000351431
18 MAIA H , HADDAD C , CASOY J et al. Effect of a hormone-releasing intrauterine system (Mirena(?)) on aromatase and Cox-2 expression in patients with adenomyosis submitted or not, to endometrial resection[J]. Int J Womens Health, 2012, 4 175- 183
19 YU Q , ZHANG S , LI H et al. Dienogest for treatment of endometriosis in women:a 28-week, open-label, extension study[J]. J Womens Health(Larchmt), 2019, 28 (2): 170- 177
doi: 10.1089/jwh.2018.7084
20 FAWZY M , MESBAH Y . Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis:a prospective clinical trial[J]. Arch Gynecol Obstet, 2015, 292 (6): 1267- 1271
doi: 10.1007/s00404-015-3755-5
21 OSUGA Y , FUJIMOTO-OKABE H , HAGINO A . Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis:a randomized, double-blind, multicenter, placebo-controlled study[J]. Fertil Steril, 2017, 108 (4): 673- 678
doi: 10.1016/j.fertnstert.2017.07.021
22 NERⅡSHI K , HIRATA T , FUKUDA S et al. Long-term dienogest administration in patients with symptomatic adenomyosis[J]. J Obstet Gynaecol Res, 2018, 44 (8): 1439- 1444
doi: 10.1111/jog.2018.44.issue-8
23 MATSUSHIMA T , AKIRA S , FUKAMI T et al. Efficacy of hormonal therapies for decreasing uterine volume in patients with adenomyosis[J]. Gynecol Minim Invasive Ther, 2018, 7 (3): 119- 123
doi: 10.4103/GMIT.GMIT_35_18
24 PONPUCKDEE J , TANEEPANICHSKUL S . The effects of implanon in the symptomatic treatment of endometriosis[J]. J Med Assoc Thai, 2005, 88 Suppl 2 S7- S10
25 WU J , HUANG Y , CHEN L et al. Treatment of adenomyosis with subcutaneous etonogestrel implants:a clinical observational study in 17 patients[J]. Med Sci Monit, 2018, 24 6085- 6092
doi: 10.12659/MSM.908979
26 NELSON J R , CORSON S L . Long-term management of adenomyosis with a gonadotropin-releasing hormone agonist:a case report[J]. Fertil Steril, 1993, 59 (2): 441- 443
doi: 10.1016/S0015-0282(16)55704-5
27 KHAN K N , KITAJIMA M , HIRAKI K et al. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy[J]. Hum Reprod, 2010, 25 (3): 642- 653
doi: 10.1093/humrep/dep437
28 PIERCE S J , GAZVANI M R , FARQUHARSON R G . Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis:a randomized trial with a 6-year follow-up[J]. Fertil Steril, 2000, 74 (5): 964- 968
doi: 10.1016/S0015-0282(00)01537-5
29 TANG H , WU R , LI X et al. Curative effect of 1.88-mg and 3.75-mg gonadotrophin-releasing hormone agonist on stage Ⅲ-Ⅳ endometriosis:Randomized controlled study[J]. J Obstet Gynaecol Res, 2017, 43 (10): 1550- 1554
doi: 10.1111/jog.2017.43.issue-10
30 孙长亮.超小剂量米非司酮治疗子宫腺肌病患者的疗效观察[J/CD].实用妇科内分泌杂志(电子版), 2016, 3(2): 116, 118.
SUN Changliang. Efficacy of low-dose mifepristone in treatment of adenomyosis[J/CD]. Journal of Practical Gynecologic Endocrinology(Electronic Edition), 2016, 3(2): 116, 118. (in Chinese)
31 NEWFIELD R S , SPITZ I M , ISACSON C et al. Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia[J]. Clin Endocrinol(Oxf), 2001, 54 (3): 399- 404
doi: 10.1046/j.1365-2265.2001.01026.x
32 刘芳, 王承秀 . 孕三烯酮与米非司酮治疗子宫腺肌病80例临床效果分析[J]. 现代诊断与治疗, 2014, 25 (13): 2996- 2997
LIU Fang , WANG Chengxiu . Clinical analysis of gestrinone and mifepristone in treatment of 80 patients with adenomyosis[J]. Modern Diagnosis & Treatment, 2014, 25 (13): 2996- 2997
[1] 叶萍仙, 叶萍贞, 何锦平. 曲美他嗪对高血压合并糖尿病患者心功能及运动耐量的影响[J]. 浙江大学学报（医学版）, 2019, 48(3): 282-288.
[2] 马竞, 何文龙, 高重阳, 余瑞云, 薛鹏, 牛永超. 木瓜苷通过抑制NF-κB P65/TNF-α通路活性减轻小鼠脑缺血再灌注诱导的组织损伤[J]. 浙江大学学报（医学版）, 2019, 48(3): 289-295.
[3] 朱紫菱, 谈静, 邓红. 肿瘤细胞膜/质蛋白转位入核研究进展[J]. 浙江大学学报（医学版）, 2019, 48(3): 318-325.
[4] 张建民. 缺血性脑血管疾病手术治疗新进展[J]. 浙江大学学报（医学版）, 2019, 48(3): 233-240.
[5] 吴雨星, 张世红, 陈忠. 缰核及其神经环路在神经精神疾病中的作用研究进展[J]. 浙江大学学报（医学版）, 2019, 48(3): 310-317.
[6] 张韵竹, 朱春鹏, 陆新良. 胃癌早期诊断的血清生物学标志物研究进展[J]. 浙江大学学报（医学版）, 2019, 48(3): 326-333.
[7] 张信美,徐萍. 子宫腺肌病分层治疗及管理[J]. 浙江大学学报（医学版）, 2019, 48(2): 123-129.
[8] 楼俊瑶,黄秀峰,张丽凤,徐萍,张信美,陈正云. 第二代子宫内膜消融术可提高左炔诺孕酮宫内节育系统对子宫腺肌病患者的疗效[J]. 浙江大学学报（医学版）, 2019, 48(2): 136-141.
[9] 吴彬彬,杨毅. 心脏手术相关急性肾损伤早期生物学标志物研究进展[J]. 浙江大学学报（医学版）, 2019, 48(2): 224-229.
[10] 张丽凤,杨慧,张信美,陈正云. 左炔诺孕酮宫内节育系统治疗子宫腺肌病患者的疗效和不良反应观察[J]. 浙江大学学报（医学版）, 2019, 48(2): 130-135.
[11] 杨坤,胡晓晟. 微小RNA-21在心脏疾病中的研究进展[J]. 浙江大学学报（医学版）, 2019, 48(2): 214-218.
[12] 徐力,许鸣,童向民. 有氧糖酵解在非霍奇金淋巴瘤发病及耐药机制中的作用[J]. 浙江大学学报（医学版）, 2019, 48(2): 219-223.
[13] 赵世浩,张雪,柯越海. 细胞衰老与特发性肺纤维化的相关性研究进展[J]. 浙江大学学报（医学版）, 2019, 48(1): 111-115.
[14] 宋方俊,郭江涛. 电压门控离子通道结构生物学研究进展[J]. 浙江大学学报（医学版）, 2019, 48(1): 25-33.
[15] 史婧,冯钰. 细菌RNA聚合酶抑制剂的分子生物学机制研究进展[J]. 浙江大学学报（医学版）, 2019, 48(1): 44-49.